Literature DB >> 3158095

Neutralisation of heparan sulphate and low molecular weight heparin by protamine.

A R Hubbard, C A Jennings.   

Abstract

The neutralisation by protamine sulphate (PS) of heparan sulphate (HS), a low molecular weight heparin (LMWH), and a reference preparation of unfractionated heparin (UH), was studied by activated partial thromboplastin time (APTT) and anti-Xa clotting assays. UH was most easily neutralised in the APTT assay by PS (on a weight for weight basis), followed by LMWH and HS. The neutralisation of APTT activity by PS closely followed the loss of activity in the anti-Xa clotting assay, when plasma was used as the source of At III. When the anti-Xa clotting assay was carried out using purified At III in place of plasma, HS and LMWH were neutralised by much lower amounts of PS and resembled UH neutralisation more closely. Resistance of HS anti-Xa activity to PS neutralisation decreased with increasing plasma dilution. The presence of bovine albumin with purified At III concentrate increased the resistance of HS to PS neutralisation. It is concluded that PS binding to UH, HS and LMWH is probably related more to their degree of sulphation than molecular weight and that non-specific interactions between PS and plasma proteins inhibit the binding of PS to HS and LMWH.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158095

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

Review 1.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

2.  Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.

Authors:  R Mastacchi; M Barbanti; P Bianchini; B Osima
Journal:  Agents Actions       Date:  1986-03

Review 3.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 4.  Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders.

Authors:  H A Friedel; J A Balfour
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

5.  The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target.

Authors:  Bartlomiej Kalaska; Joanna Miklosz; Kamil Kamiński; Bogdan Musielak; Shin-Ichi Yusa; Dariusz Pawlak; Maria Nowakowska; Krzysztof Szczubiałka; Andrzej Mogielnicki
Journal:  RSC Adv       Date:  2019-01-23       Impact factor: 4.036

6.  High Preoperative Serum Syndecan-1, a Marker of Endothelial Glycocalyx Degradation, and Severe Acute Kidney Injury after Valvular Heart Surgery.

Authors:  Hye-Bin Kim; Sarah Soh; Young-Lan Kwak; Jae Chan Bae; Sang Hwa Kang; Jong Wook Song
Journal:  J Clin Med       Date:  2020-06-10       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.